foxo4-dri senolytic 2023 2024 study part 1 , #peptide #molecule #research #health #information Frontiers | Senolytic Peptide FOXO4-DRI

Morozov V.G., Khavinson V.K

Good candidates for MINT Threads have relatively even skin texture and should not have excessively thin or thick skin

Retatrutide monotherapy achieved 24.2% weight reduction in phase 2 trials, while cagrilintide combined with semaglutide (CagriSema) reached 22.7%

It seems more political than scientifically based when you draw distinctions that dont exist between these types of vaccines

A reasonable candidate is someone who: Is already following a structured, clinician-supervised nutrition and activity plan Has a documented B12 deficiency or a condition that impairs B12 absorption Cannot tolerate GLP-1 medications, or is not a candidate for them Declines prescription pharmacotherapy and wants a non-stimulant, non-surgical adjunct Understands because the clinician has said so plainly that the injection is a supporting player A poor candidate is someone who wants the shot instead of the program